Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 49, 2, (550-562), 10.1007/s00259-021-05489-8)

Research output: Contribution to journalComment/debate

Fingerprint

Dive into the research topics of 'Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 49, 2, (550-562), 10.1007/s00259-021-05489-8)'. Together they form a unique fingerprint.

Medicine & Life Sciences